Tricuspid Regurgitation: How Will Valve Repair Change Our Practice?
Overview
Severe tricuspid regurgitation remains an unmet need, given the adverse outcomes and symptom burden associated with it. It is estimated that >70 million people worldwide currently have some degree of tricuspid regurgitation. Until recently, surgical intervention and medical therapy were the main treatment modalities, however, transcatheter repair is now an option for many people – particularly where the risk associated with surgery is elevated.
This live broadcast, chaired by Prof Ralph Stephan von Bardeleben (Heart Valve Center, Mainz, DE), aims to bring the community up to date with the latest clinical data on tricuspid valve repair techniques and to identify those patients who stand to gain most benefit from repair-based approaches compared with surgery or medical therapy alone.
Want to find out more about the recent TRILUMINATE Pivotal Trial Results?
Key Learning Objectives
- Review existing real-world and RCT evidence on tricuspid valve repair
- Assess relative effectiveness of existing modes of treatment for severe tricuspid regurgitation
- Identify key patient groups who may benefit from device-based valve repair over surgical repair or medical therapy
- Recall what recent advances in the field of device-based repair means for real-world practice
- Apply emerging data and expert guidance to current practice
Target Audience
- Cardiologists
- Interventional Cardiologists
- Surgeons
- Heart Failure Specialists
